Moderna (CHIX:0QFD) Other Current Liabilities: €647 Mil (As of Mar. 2026)


CHIX:0QFD Moderna Inc CHIX:0QFD
67 GF Score
Price €70.49
GF Value €20.23
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Moderna Other Current Liabilities?

Moderna CHIX:0QFD 67 Other Current Liabilities is €647 Mil as of Mar. 2026. GuruFocus rates CHIX:0QFD with a GF Score™ of 67/100 and a GF Value™ of €20.23 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Moderna's other current liabilities for the quarter that ended in Mar. 2026 was €647 Mil.

Moderna's quarterly other current liabilities increased from Sep. 2025 (€648 Mil) to Dec. 2025 (€915 Mil) but then declined from Dec. 2025 (€915 Mil) to Mar. 2026 (€647 Mil).

Moderna's annual other current liabilities increased from Dec. 2023 (€772 Mil) to Dec. 2024 (€827 Mil) and increased from Dec. 2024 (€827 Mil) to Dec. 2025 (€915 Mil).

Moderna Other Current Liabilities Related Terms

Moderna Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Moderna's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moderna Other Current Liabilities Chart

Moderna Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 123.90 229.39 772.11 827.03 915.49

Moderna Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 616.05 567.02 648.37 915.49 647.02
CHIX:0QFD
67GF Score
Moderna Inc CHIX:0QFD
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Moderna Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of €647 Mil mean?
Moderna (CHIX:0QFD) has a Other Current Liabilities of €647 Mil as of Mar. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Moderna.
Is Moderna's Other Current Liabilities too high?
Moderna's current Other Current Liabilities is €647 Mil. Overall, Moderna has a GF Score™ of 67/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Moderna's Other Current Liabilities compare to RPRX and ROIV?
Moderna's Other Current Liabilities of €647 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Biotechnology company?
A good Other Current Liabilities depends on the Biotechnology industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Moderna. Moderna's current Other Current Liabilities is €647 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moderna stock overvalued right now?
Based on GuruFocus' analysis, Moderna (CHIX:0QFD) is currently considered Significantly Overvalued. The stock's GF Value™ is €20.23, compared to a current price of €70.49 — trading 248.4% above its estimated fair value. The current Other Current Liabilities is €647 Mil. Moderna's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Moderna (CHIX:0QFD), the current Other Current Liabilities is €647 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moderna (CHIX:0QFD) Overvalued in 2026?

Based on GuruFocus' analysis, Moderna stock appears to be overvalued. The current stock price of €70.49 is trading 248.4% above its estimated GF Value™ of €20.23. GuruFocus considers Moderna to be Significantly Overvalued.

Key valuation signals for CHIX:0QFD:

  • Other Current Liabilities: €647 Mil
  • GF Value™: €20.23 vs. price of €70.49 (248.4% above fair value)
  • GF Score™: 67/100 with 7 warning signs

No single metric tells the full story. See the CHIX:0QFD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moderna Business Description

Address 325 Binney Street, Cambridge, MA, USA, 02142
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
67GF Score

Get the complete analysis for CHIX:0QFD

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€70.49
Price
€20.23
GF Value